Effect of angiotensin II receptor blocker therapy on markers of fibrosis and immune inflammation in hypertensive patients with chronic kidney disease after ischemic stroke
Open Access
- 28 November 2021
- journal article
- research article
- Published by Silicea - Poligraf, LLC in Cardiovascular Therapy and Prevention
- Vol. 20 (7) , 3078
Abstract
Aim. To compare the effect of angiotensin II receptor blocker therapy (azilsartan, telmisartan) on fibrosis and immune inflammation markers in hypertensive patients with chronic kidney disease (CKD) after ischemic stroke (IS).Material and methods. The study included 76 hypertensive patients aged 60-74 years (mean age, 66±5 years) with CKD after IS. Patients were randomly divided into following pharmacotherapy groups: 38 patients — telmisartan group; 36 patients — azilsartan group. The control group consisted of 20 hypertensive people (mean age, 63±2 years) without a history of CKD and IS. The levels of matrix metalloproteinase 9 (MMP-9) and tissue inhibitor of metalloproteinase-1 (TIMP-1) were determined by enzyme-linked immunosorbent assay (ELISA Kit, USA). The levels of interleukin-1β (IL-1β), tumor necrosis factor α (TNF-α), interferon γ (INF-γ), monocytic chemoattractant protein 1 (MCP-1) were assessed using Vector-Best kit (Russia).Results. Six-month azilsartan therapy led to a decrease in the levels of MMP-9 by 19,9% (pConclusion. Six-month telmisartan therapy in hypertensive patients with CKD after stroke was accompanied by a more pronounced decrease in markers of myocardial fibrosis (MMP-9, TIMP-1) and immune inflammation (TNF-α, INF-γ, MCP-1) compared with azilsartan, as well as with more pronounced improvement in renal function.Keywords
This publication has 32 references indexed in Scilit:
- Chronic kidney disease and the risk of stroke: a systematic review and meta-analysisNephrology Dialysis Transplantation, 2015
- THE PREVALENCE OF NON-INFECTIOUS DISEASES RISK FACTORS IN RUSSIAN POPULATION IN 2012-2013 YEARS. THE RESULTS OF ECVD-RFCardiovascular Therapy and Prevention, 2014
- Nephrosclerosis: update on a centenarianNephrology Dialysis Transplantation, 2014
- Chronic Kidney Disease and StrokeAdvances in Chronic Kidney Disease, 2014
- Prevention and Intervention Studies with Telmisartan, Ramipril and Their Combination in Different Rat Stroke ModelsPLOS ONE, 2011
- Matrix Metalloproteinase-9 as a Marker for Acute Ischemic Stroke: A Systematic ReviewJournal of Stroke and Cerebrovascular Diseases, 2011
- Angiotensin receptor type 1 antagonists protect against neuronal injury induced by oxygen–glucose depletionBritish Journal of Pharmacology, 2010
- Renal outcomes with different fixed-dose combination therapies in patients with hypertension at high risk for cardiovascular events (ACCOMPLISH): a prespecified secondary analysis of a randomised controlled trialThe Lancet, 2010
- Long-Term Renoprotective Effects of Standard Versus High Doses of Telmisartan in Hypertensive Nondiabetic NephropathiesAmerican Journal of Kidney Diseases, 2005
- Provision of cardiovascular protection by ACE inhibitors:a review of recent trialsCurrent Medical Research and Opinion, 2004